Patents Issued in April 18, 2019
  • Publication number: 20190111038
    Abstract: Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.
    Type: Application
    Filed: April 12, 2017
    Publication date: April 18, 2019
    Inventor: Arturo SOLIS HERRERA
  • Publication number: 20190111039
    Abstract: The present invention provides a method of treating symptoms associated with Androgen Deprivation Therapy comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 18, 2019
    Applicant: Eli Lilly and Company
    Inventors: Charles Thomas BENSON, Rachel Nicole RICHEY, Hannah YU
  • Publication number: 20190111040
    Abstract: In accordance with the present invention, the immunoregulatory activity of low doses of P4N was investigated. Unlike previously described antitumor drugs, low dose P4N, in doses of about 1 to 10 mg/kg, or at concentrations of about 10 to 100 nM, was surprisingly found to contribute to humoral immunity by raising the titers and activities of autoantibodies against GRP78 and F1F0 ATP synthase on the surface of CT26 cells, and inducing B cell proliferation and differentiation of plasma cells. Methods for inducing endogenous antitumor autoantibodies (EAA) in a subject having a neoplasia comprising administering to the subject an effective amount of the nordihydroguaiaretic acid (NDGA) derivative P4N, or salts, solvates and stereoisomers thereof, as well as methods for inducing B cell proliferation, inducing BAFF stimulated B cell proliferation, and suppressing or inhibition growth of a neoplasia are also provided.
    Type: Application
    Filed: March 30, 2017
    Publication date: April 18, 2019
    Inventors: Ru Chih C. Huang, David Mold, Tiffany Jackson, Yu-Ling Lin, Kuang-Wen Liao
  • Publication number: 20190111041
    Abstract: The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximioyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.
    Type: Application
    Filed: April 28, 2017
    Publication date: April 18, 2019
    Inventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Catherine Kolster Fog-Tonnesen, Nikolaj Havnsøe Torp Petersen, Claus Bornæs
  • Publication number: 20190111042
    Abstract: Methods of treating symptoms of skin disorders with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in pruritis, xerosis, or other skin disorder-affected function. Skin disorders upon which the methods of the invention can improve symptoms and causes of the disorders include eczema, bullous pemphigoid, atopic dermatitis, and psoriasis.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Inventors: Steven P. Braithwaite, S. Sakura Minami, Arnaud E.J. Teichert
  • Publication number: 20190111043
    Abstract: The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 18, 2019
    Applicants: NATIONAL CANCER CENTER, Eisai R&D Management Co., Ltd.
    Inventors: Tatsuhiro SHIBATA, Yasuhito ARAI, Kenichi NOMOTO, Tomio NAKAMURA, Akihiko TSURUOKA, Saori MIYANO
  • Publication number: 20190111044
    Abstract: This invention provides, among other things, tetrahydroisoquinolines useful for treating viral infections, pharmaceutical formulations containing such compounds, as well as methods of inhibiting the replication of a virus, such as HIV, or treating a disease, such as AIDS.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 18, 2019
    Inventors: Andy ATUEGBU, Dennis SOLAS, Clarence R. HURT, Anatoliy KITAYGORODSKYY
  • Publication number: 20190111045
    Abstract: Pharmaceutical ophthalmic compositions are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), a combination of at least two solubilizing and suspending agents (of which one is a non-ionic polyoxyethlene-polyoxypropylene block copolymer), and a carrier. Methods for fabricating the compositions and using them are also described.
    Type: Application
    Filed: May 3, 2017
    Publication date: April 18, 2019
    Inventors: William Wiley, Richard Dilzer, Dennis Elias Saadeh, Jeffrey T. Liegner, John Scott Karolchyk, Bernard Covalesky, Kallan Peters
  • Publication number: 20190111046
    Abstract: The present invention provides a combination of at least one oxazolidinone-quinolone hybrid with at least one further antibacterial compound and the use thereof as drug, especially for the treatment or prophylaxis of bacterial infections.
    Type: Application
    Filed: June 11, 2018
    Publication date: April 18, 2019
    Inventors: Thomas Kapsner, Axel Dalhoff
  • Publication number: 20190111047
    Abstract: The present disclosure is related to methods of treating agitation and/or aggression and/or associated symptoms in subjects with dementia, including, dementia associated with Alzheimer's disease. The method includes administering to a subject in need thereof a dextromethorphan compound, or a pharmaceutically acceptable salt thereof, in combination with quinidine, or a pharmaceutically acceptable salt thereof. The disclosure in certain aspects is also related to compositions that are used for treating agitation and/or aggression and/or associated symptoms in subjects suffering from Alzheimer's disease.
    Type: Application
    Filed: September 14, 2015
    Publication date: April 18, 2019
    Inventor: Joao SIFFERT
  • Publication number: 20190111048
    Abstract: The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.
    Type: Application
    Filed: November 1, 2017
    Publication date: April 18, 2019
    Applicant: BioDelivery Sciences International, Inc.
    Inventors: Andrew Finn, Niraj Vasisht
  • Publication number: 20190111049
    Abstract: Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders or to produce analgesia.
    Type: Application
    Filed: May 11, 2018
    Publication date: April 18, 2019
    Inventors: Lawrence R. JAMES, Laura A. JAMES
  • Publication number: 20190111050
    Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: KLAUS WENING, ANJA GEIßLER- FICHTNER, JANA DENKER, LUTZ BARNSCHEID
  • Publication number: 20190111051
    Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 18, 2019
    Inventors: Frank S. Caruso, Huai-Hung Kao
  • Publication number: 20190111052
    Abstract: The present application relates to new uses of 5-HT6 receptor antagonists, specifically high doses of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, and to the combination of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, with, an acetylcholinesterase inhibitor for the treatment of a neurodegenerative disease.
    Type: Application
    Filed: July 19, 2018
    Publication date: April 18, 2019
    Inventors: Lawrence Tim FRIEDHOFF, Stephen Clement PISCITELLI, Kunal KISHNANI, Shankar RAMASWAMY, Bryan M. LEWIS
  • Publication number: 20190111053
    Abstract: This invention provides a method of treating myelodysplastic syndrome in a human subject afflicted therewith comprising administering to the subject an amount from 0.1 mg/m2 to 5 mg/m2 of a compound having the structure (I) or a salt, zwitterion, or ester thereof.
    Type: Application
    Filed: January 27, 2017
    Publication date: April 18, 2019
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • Publication number: 20190111054
    Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and/or neuronal death. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, Parkinson's disease, Lewy body dementia, multiple system atrophy and other related synucleinopathies, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on 3-phenylsulfonyl-8-(piperazin-1-yl) quinolone and baclofen and/or acamprosate.
    Type: Application
    Filed: February 3, 2017
    Publication date: April 18, 2019
    Inventors: DANIEL COHEN, SERGUEI NABIROTCHKIN, RODOLPHE HAJJ
  • Publication number: 20190111055
    Abstract: The present invention pertains to the technological sector of the pharmaceutical industry and, more specifically, refers to a second use composition intended for the treatment of a dermatology condition called Poikiloderma of Civatte. The solution proposed in this document is the use of a topical composition containing any substance alone or in combination from the pharmacological group of alpha-adrenergic receptor agonists in therapeutic quantities to treat color of the lesions of Poikiloderma of Civatte. The application of this composition for the condition of Poikiloderma of Civatte results in significant improvement of the color of the skin lesions, also improving the vascular component present in this condition and can be associated with other compounds.
    Type: Application
    Filed: March 22, 2017
    Publication date: April 18, 2019
    Inventor: Doris Maria Hexsel
  • Publication number: 20190111056
    Abstract: Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof.
    Type: Application
    Filed: March 21, 2017
    Publication date: April 18, 2019
    Inventors: Lei JIANG, Meiyu GENG, Qiangang ZHENG, Min HUANG, Huixin WAN, Shuai TANG, Xianlei FU, Xiaojing LAN, Jianhua CAO, Feifei LIU, Jian DING
  • Publication number: 20190111057
    Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
    Type: Application
    Filed: November 20, 2018
    Publication date: April 18, 2019
    Applicant: AstraZeneca AB
    Inventors: Cindy FINNIE, Steven Anthony RAW, David WILSON
  • Publication number: 20190111058
    Abstract: This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS).
    Type: Application
    Filed: May 15, 2018
    Publication date: April 18, 2019
    Inventor: Krishna Vaddi
  • Publication number: 20190111059
    Abstract: A method of treating suffering from a CNS disorder, comprising administering a reduced folate, or a derivative, prodrug, active metabolite, stereoisomer, polymorph, analogue, or pharmaceutically acceptable salt thereof, to a human suffering from a neurobehavioral CNS disorder in which the patient exhibits a folate deficiency, wherein the amount of reduced folate is therapeutically effective to improve at least one core symptom of the CNS disorder, is disclosed.
    Type: Application
    Filed: October 17, 2018
    Publication date: April 18, 2019
    Applicant: Marinus Pharmaceuticals, Inc.
    Inventors: Richard Frye, John Slattery
  • Publication number: 20190111060
    Abstract: Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 18, 2019
    Applicant: Pfizer Inc.
    Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue, Ryan Patman
  • Publication number: 20190111061
    Abstract: An object of the present invention to provide therapeutic compositions and methods for the prevention and/or treatment of airway obstructive disorders that involve bronchial hyper-responsiveness (BHR), asthma, horse asthma, airway remodeling that potentiate BHR, and any other airway obstructive disorders that involve bronchial smooth muscle (BSM) constriction or possibly other airway smooth muscle (ASM) constriction in a subject in need thereof. Compositions and methods for targeting HCN channels in airway smooth muscle to treat and/or prevent asthma and asthma-like conditions are disclosed. The compositions and methods include administering a therapeutically effective amount of HCN channel blocker, preferably ivabradine hydrochloride, to a subject in need thereof.
    Type: Application
    Filed: April 3, 2017
    Publication date: April 18, 2019
    Applicant: Mississippi State University
    Inventors: Cyprianna Swiderski, Courtney Hunter
  • Publication number: 20190111062
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: December 7, 2018
    Publication date: April 18, 2019
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Publication number: 20190111063
    Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
    Type: Application
    Filed: October 17, 2018
    Publication date: April 18, 2019
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • Publication number: 20190111064
    Abstract: A pharmaceutical composition and method reduces statin-related side effects, including myalgia, myositis, myopathy, and myonecrosis. The composition comprises at least one HMG-CoA reductase inhibitor (statin) and vitamin D. The composition may comprise one or more excipient. The pharmaceutical composition is adapted to decrease side effects of said HMG-CoA reductase inhibitors. The excipient may comprise one or more excipient delivery agent providing immediate release, sustained release, extended release and/or combination thereof of said HMG-CoA and/or vitamin D. The amount of the vitamin D may be fixed or variable. A method of treating hyperlipidemia is provided comprising an orally administered pharmaceutical composition having at least one HMG-CoA reductase inhibitor and vitamin D. Preferably, the pharmaceutical composition is administered once per day, via oral, nonoral, transdermal and/or injection drug delivery.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 18, 2019
    Applicant: Interstice Therapeutics, LLC
    Inventor: Andrew Isaacs
  • Publication number: 20190111065
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 18, 2019
    Inventor: Herriot Tabuteau
  • Publication number: 20190111066
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: November 14, 2018
    Publication date: April 18, 2019
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Publication number: 20190111067
    Abstract: The present invention relates to the use of one or more compounds selected from the following: carvacrol, thymol, curcumin and piperidine, in combination with an aminoglycoside, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The present invention also relates to novel combinations comprising one or more compounds selected from the following: carvacrol, thymol, curcumin and piperidine, in combination with an aminoglycoside, for use in the treatment of microbial infections.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 18, 2019
    Applicant: HELPERBY THERAPEUTICS LIMITED
    Inventors: Anthony COATES, Yanmin HU
  • Publication number: 20190111068
    Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
    Type: Application
    Filed: July 20, 2018
    Publication date: April 18, 2019
    Inventors: Ben Chal, Erik Mogalian, Reza Oliyai, Rowchanak Pakdaman, Dimitrios Stefanidis, Vahid Zia
  • Publication number: 20190111069
    Abstract: The present invention relates to the use of adenosine receptor modulators to affect the circadian rhythm, in particular, to the use of such modulators for the treatment of circadian rhythm disorders. In particular, the invention relates to a composition comprising at least one selective adenosine receptor modulator, wherein said composition modulates two or three, but not all of adenosine receptor subtypes A1, A2A, A2B and/or A3 for use in the treatment of circadian rhythm disorders or for modulating a biological clock.
    Type: Application
    Filed: April 12, 2017
    Publication date: April 18, 2019
    Inventors: Sridhar Vasudevan, Aarti Jagannath, Russell Foster
  • Publication number: 20190111070
    Abstract: Double stranded mRNA. e.g., produced in vitro, as well as method of making and using the ds mRNA, are provided.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 18, 2019
    Inventors: Kevin G. Rice, Samuel T. Crowley
  • Publication number: 20190111071
    Abstract: The invention solves the problem of providing new therapies that are effective in the treatment of muscular dystrophies through the use of compositions comprising a compound capable of reducing the expression of miRNA-106b in muscle satellite stem cells of a human or animal subject with respect to the expression observed in the absence of the compound in said cells.
    Type: Application
    Filed: May 12, 2016
    Publication date: April 18, 2019
    Inventors: Amelia Eva Aranega Jimenez, Diego Franco Jaime, Francisco Hernandez Torres, Estefania Lozano Velasco, Daniel Vallejo Pulido
  • Publication number: 20190111072
    Abstract: The invention concerns a trans-splicing RNA (tsRNA) molecule comprising one or multiple unstructured binding domains; a cell or vector comprising said tsRNA; and a method for killing cells or treating a disease using said tsRNA.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 18, 2019
    Applicant: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Volker PATZEL, Sushmita PODDAR
  • Publication number: 20190111073
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: October 16, 2018
    Publication date: April 18, 2019
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
  • Publication number: 20190111074
    Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
    Type: Application
    Filed: November 15, 2018
    Publication date: April 18, 2019
    Inventors: David J. Lockhart, Brandon Wustman, Mirko Hennig, Daniella Ishimaru
  • Publication number: 20190111075
    Abstract: The present invention relates to a drop-forming, storage stable, multiphase, ophthalmic composition comprising at least one liquid aqueous phase and at least one liquid hydrophobic phase, characterized in that it is emulsifier-free as well as buffer-free and comprises hyaluronic acid and/or hyaluronate.
    Type: Application
    Filed: April 12, 2017
    Publication date: April 18, 2019
    Inventors: Günther BELLMAN, Lutz KRÖHNE
  • Publication number: 20190111076
    Abstract: A method for synthesizing high purity montmorillonite is disclosed. According to this synthesis method, bentonite is dissolved in aqua regia to produce a solution and then sodium hydroxide (NaOH) is added to the solution to produce a mixed solution. Then, the mixed solution is kept in a sealed state at a temperature of 90° C. inclusive to 100° C. exclusive to synthesize montmorillonite crystals.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Inventors: Sung Man Seo, II Mo Kang, Ki Min Roh, Dae Young Kim, Jae Hwan Kim
  • Publication number: 20190111077
    Abstract: The conjugation of luteinizing hormone-releasing hormone (LHRH) with activated cisplatin using a malonate linker gives rise to a new Platinum-LHRH conjugate that effectively targets tumor cells that express the LHRH receptor. The Pt-LHRH conjugate may be used in a method for killing or inhibiting the growth of a tumor cell, especially in late state, highly invasive and aggressive stage IV tumors and in reoccurring tumors.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Applicant: Eastern Kentucky University
    Inventors: Margaret Ndinguri, Lindsay Calderon
  • Publication number: 20190111078
    Abstract: An antigen-loaded nanogel is formed by loading or encapsulating one or more long peptide antigens or one or more protein antigens in a hydrophobized polysaccharide. The long peptide antigen(s) or protein antigen(s) contains (or each contain) one or more CD8+ cytotoxic T cell recognition epitopes and/or one or more CD4+ helper T cell recognition epitopes, which is/are derived from the antigen. The antigen-loaded nanogel may be administered prior to administration of antigen-specific T cells to improve the efficacy of a T cell infusion therapy against an immune checkpoint inhibitor-resistant tumor. The hydrophobized polysaccharide may be pullulan having cholesteryl groups bound thereto. An immune-enhancing agent also may be administered in or with the antigen-loaded nanogel.
    Type: Application
    Filed: February 8, 2017
    Publication date: April 18, 2019
    Applicants: MIE UNIVERSITY, KYOTO UNIVERSITY
    Inventors: Hiroshi SHIKU, Naozumi HARADA, Daisuke MURAOKA, Kazunari AKIYOSHI
  • Publication number: 20190111079
    Abstract: Multi-specific antigen-binding constructs that target immunotherapeutics are described. The multi-specific antigen-binding constructs comprise a first antigen-binding polypeptide construct that binds to an immunotherapeutic (such as a CAR-T cell or a bispecific T-cell engager), and a second antigen binding polypeptide construct that binds to a tumour-associated antigen. Also described are methods of using the multi-specific antigen-binding constructs to re-direct or enhance the binding of the immunotherapeutic to a tumour cell, and methods of treating patients who have relapsed from or failed treatment with the immunotherapeutic.
    Type: Application
    Filed: April 13, 2017
    Publication date: April 18, 2019
    Inventor: David M. Mills
  • Publication number: 20190111080
    Abstract: Disclosed herein are methods and compositions including antigen-binding polypeptides comprising a stalk region and a stalk extension region. In some cases, the antigen-binding compositions comprising the stalk extension region has increased expression on a cell surface and, in some cases, has increased antigen-binding efficiency. A subject antigen binding polypeptide can be a chimeric antigen receptor (CAR).
    Type: Application
    Filed: October 17, 2018
    Publication date: April 18, 2019
    Inventor: Rutul R. SHAH
  • Publication number: 20190111081
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: December 27, 2018
    Publication date: April 18, 2019
    Inventors: ANDREA MAHR, TONI WEINSCHENK, ANITA WIEBE, COLETTE SONG, OLIVER SCHOOR, JENS FRITSCHE, HARPREET SINGH
  • Publication number: 20190111082
    Abstract: The present invention provides methods for inducing tolerance and/or suppressing an immune response to an antigen by passing a cell suspension containing an anucleate cell through a constriction, wherein the constriction deforms the cell thereby causing a perturbation of the cell such that an antigen and/or tolerogenic factor enters the cell. In some embodiments, the anucleate cell is delivered to an individual and the antigen is delivered to and processed in a tolerogenic environment to induce tolerance and/or suppress an immune response to the antigen.
    Type: Application
    Filed: May 3, 2017
    Publication date: April 18, 2019
    Inventors: Jonathan B. GILBERT, Bu WANG, Scott LOUGHHEAD, Howard BERNSTEIN, Armon R. SHAREI, Finola MOORE
  • Publication number: 20190111083
    Abstract: A composition comprising a protein source and an antioxidant, optionally in combination with an omega-3 fatty acid, can treat or prevent sarcopenia in elderly males, reduce a loss of muscle functionality (e.g. muscle strength, gait speed, etc.) in elderly males, increase muscle functionality in elderly males, and/or improve recovery of muscle functionality after muscle atrophy in elderly males.
    Type: Application
    Filed: October 9, 2015
    Publication date: April 18, 2019
    Inventors: Denis Breuille, Toshio Moritani, Gerard Vinyes Pares
  • Publication number: 20190111084
    Abstract: The present invention discloses a method for remolding bone marrow microenvironment in a subject having an impaired bone marrow microenvironment, which comprises implanting a composition comprising isolated mesenchymal stromal cells (MSCs) into the bone marrow cavity of the subject. The method of the present invention successfully remolds the bone marrow microenvironment, recovers the normal hematopoiesis of bone marrow, inhibits/delays the pathological process of leukemia and significantly prolongs the survival period. In addition, the method according to the present invention can be used for the treatment of hematologic tumors such as leukemia and aplastic anemia (AA), which is safe and effective but has no side effects.
    Type: Application
    Filed: January 12, 2018
    Publication date: April 18, 2019
    Inventors: Jinyong Wang, Chengxiang Xia, Yong Dong, Tongjie Wang, Xiaofei Liu, Juan Du, Yang Geng, Lijuan Liu, Hongling Wu
  • Publication number: 20190111085
    Abstract: The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Inventors: Daniel Shoemaker, David Robbins, John D. Mendlein, Caroline Desponts
  • Publication number: 20190111086
    Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR? primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii.
    Type: Application
    Filed: May 11, 2018
    Publication date: April 18, 2019
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventors: Gordon KELLER, April M. CRAFT
  • Publication number: 20190111087
    Abstract: The present application is directed to the field of implants comprising soft tissue for use in implantation in humans. The soft tissue implants of the present application are preferably obtained from xenograft sources. The present application provides a chemical process that sterilizes, removes antigens from and/or strengthens xenograft implants. The present techniques yield soft tissue implants having superior structural, mechanical, and/or biochemical integrity. The present application is also directed to processes for treating xenograft implants comprising soft tissues such as dermis, and to implants produced by such processes.
    Type: Application
    Filed: August 27, 2018
    Publication date: April 18, 2019
    Applicant: TUTOGEN MEDICAL GMBH
    Inventors: Arnd Wilhelmi, Silke Schreiner, Jake Michaelson, Steven Moore, Jennifer Faleris, Anne Reinlein